Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KALA 
Kala Pharmaceuticals Inc (KALA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: KALA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $24.6
1 Year Target Price $24.6
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 157.62% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 128.63M USD | Price to earnings Ratio - | 1Y Target Price 24.6 |
Price to earnings Ratio - | 1Y Target Price 24.6 | ||
Volume (30-day avg) 2 | Beta -1.82 | 52 Weeks Range 2.92 - 20.60 | Updated Date 09/17/2025 |
52 Weeks Range 2.92 - 20.60 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.96 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -51.9% | Return on Equity (TTM) -708.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 126613452 | Price to Sales(TTM) 1.16 |
Enterprise Value 126613452 | Price to Sales(TTM) 1.16 | ||
Enterprise Value to Revenue 0.04 | Enterprise Value to EBITDA -0.16 | Shares Outstanding 7021040 | Shares Floating 3240912 |
Shares Outstanding 7021040 | Shares Floating 3240912 | ||
Percent Insiders 1.75 | Percent Institutions 65.5 |
Upturn AI SWOT
Kala Pharmaceuticals Inc
Company Overview
History and Background
Kala Pharmaceuticals, Inc. was founded in 2009. Initially focused on innovative nanoparticle-based ophthalmic medicines, the company underwent significant restructuring, ultimately selling its commercial assets and pivoting its focus to research and development of rare and severe diseases. Kala Pharmaceuticals Inc no longer exists, as it was acquired by Alumis Inc. and subsequently dissolved
Core Business Areas
Leadership and Structure
Kala Pharmaceuticals Inc no longer exists, as it was acquired by Alumis Inc. and subsequently dissolved
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
The ophthalmic pharmaceutical industry is characterized by intense competition, rapidly evolving technologies, and stringent regulatory requirements. The industry is focused on developing new treatments for conditions such as dry eye disease, glaucoma, and retinal disorders.
Positioning
Before acquisition, Kala Pharmaceuticals focused on developing and commercializing therapies utilizing its proprietary AMPPLIFY mucus-penetrating particle (MPP) technology. The company aimed to improve drug delivery and efficacy in ocular diseases and, after restructuring, on rare and severe diseases.
Total Addressable Market (TAM)
Prior to being acquired, Kala Pharmaceuticals was targeting significant TAMs in its therapeutic areas. It is impossible to ascertain that now
Upturn SWOT Analysis
Strengths
- Proprietary AMPPLIFY technology (before the acquisition)
- Experienced management team (before the acquisition)
- Pipeline of novel therapies (before the acquisition)
- Successful commercialization of products (before the acquisition)
Weaknesses
- High operating expenses (before the acquisition)
- Dependence on regulatory approvals (before the acquisition)
- Limited financial resources (before the acquisition)
Opportunities
- Expansion into new therapeutic areas (before the acquisition)
- Partnerships and collaborations (before the acquisition)
- Advancements in drug delivery technologies (before the acquisition)
Threats
- Competition from established pharmaceutical companies (before the acquisition)
- Generic drug entry (before the acquisition)
- Changes in regulatory landscape (before the acquisition)
- Unsuccessful clinical trials (before the acquisition)
Competitors and Market Share
Key Competitors
Competitive Landscape
Kala Pharmaceuticals Inc no longer exists, as it was acquired by Alumis Inc. and subsequently dissolved
Growth Trajectory and Initiatives
Historical Growth: Prior to acquisition, Kala Pharmaceuticals focused on growth through developing and commercializing new ophthalmic therapies.
Future Projections: No longer applicable after acquisition by Alumis Inc.
Recent Initiatives: Prior to the acquisition, Kala Pharmaceutical recent initiatives included refocusing on its research and development pipeline.
Summary
Kala Pharmaceuticals Inc. was a pharmaceutical company focused on developing and commercializing therapies. The company possessed proprietary technologies and a pipeline. Ultimately, challenges in the market led to its acquisition by Alumis Inc. and its subsequent dissolution. Before this point in time, Kala Pharmaceuticals was successful in commericalizing ophthalmic medication.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Press Releases
- Market Research Reports
- Company Website (historical data)
Disclaimers:
This analysis is based on publicly available information. Due to the acquisition and dissolution of Kala Pharmaceuticals Inc., some data may be outdated. The analysis should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kala Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Arlington, MA, United States | ||
IPO Launch date 2017-07-20 | CEO, President & Director Mr. Todd Bazemore | ||
Sector Healthcare | Industry Biotechnology | Full time employees 38 | Website https://www.kalarx.com |
Full time employees 38 | Website https://www.kalarx.com | ||
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.